ESMO 2022 Conference Coverage

 

ESMO 2022 Conference Coverage
A

ESMO 2022 on the Phase 3 VISION Trial: Comparing 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients With mCRPC

By ESMO 2022 Conference Coverage FEATURING Andrew Armstrong
By ESMO 2022 Conference Coverage FEATURING Andrew Armstrong
174 views
September 21, 2022
0 Comments
Login to view comments. Click here to Login
GU
06:54
ESMO 2022 Conference Coverage

ESMO 2022 on the JAVELIN Bladder 100 Trial: Avelumab 1L Maintenance …

Feat. J. Aragon-Ching
05:10
ESMO 2022 Conference Coverage

ESMO 2022 on the Results From the PREVAIL Prospective Cohort Study: …

Feat. P. Grivas
09:42
ESMO 2022 Conference Coverage

ESMO 2022 on the Phase 1 Study of PRL-02, a Long-Acting IM Depot Inj…

Feat. J. Avitia
05:53
ESMO 2022 Conference Coverage

ESMO 2022 Initial Results From the Phase 3 SPLASH Study: Efficacy an…

Feat. A. Hansen
02:47
ESMO 2022 Conference Coverage

ESMO 2022 on the Phase 3 VISION Trial: Comparing 177Lu-PSMA-617 Trea…

Feat. A. Armstrong
05:47
ESMO 2022 Conference Coverage

ESMO 2022 on the Impact of TURBT and Intravesical BCG vs. Radical Cy…

Feat. P. Haddad
04:35
ESMO 2022 Conference Coverage

ESMO 2022 on the 4-Factor Model to Predict Response and Survival Ben…

Feat. G. Sonpavde
12:10
ESMO 2022 Conference Coverage

ESMO 2022: Key Bladder Cancer/Urothelial Carcinoma Presentations

Feat. G. Sonpavde